The role of APOE in cerebrovascular dysfunction

The ε4 allele of the apolipoprotein E gene (APOE4) is associated with cognitive decline during aging, is the greatest genetic risk factor for Alzheimer’s disease and has links to other neurodegenerative conditions that affect cognition. Increasing evidence indicates that APOE genotypes differentially modulate the function of the cerebrovasculature (CV), with apoE and its receptors expressed by different cell types at the CV interface (astrocytes, pericytes, smooth muscle cells, brain endothelial cells). However, research on the role of apoE in CV dysfunction has not advanced as quickly as other apoE-modulated pathways. This review will assess what aspects of the CV are modulated by APOE genotypes during aging and under disease states, discuss potential mechanisms, and summarize the therapeutic significance of the topic. We propose that APOE4 induces CV dysfunction through direct signaling at the CV, and indirectly via modulation of peripheral and central pathways. Further, that APOE4 predisposes the CV to damage by, and exacerbates the effects of, additional risk factors (such as sex, hypertension, and diabetes). ApoE4-induced detrimental CV changes include reduced cerebral blood flow (CBF), modified neuron-CBF coupling, increased blood–brain barrier leakiness, cerebral amyloid angiopathy, hemorrhages and disrupted transport of nutrients and toxins. The apoE4-induced detrimental changes may be linked to pericyte migration/activation, astrocyte activation, smooth muscle cell damage, basement membrane degradation and alterations in brain endothelial cells.

[1]  Lilah M. Besser,et al.  Cerebral amyloid angiopathy and its co-occurrence with Alzheimer's disease and other cerebrovascular neuropathologic changes , 2015, Neurobiology of Aging.

[2]  Guojun Bu,et al.  ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners? , 2014, Neuron.

[3]  B. Hyman,et al.  APOEε2 is associated with milder clinical and pathological Alzheimer disease , 2015, Annals of neurology.

[4]  Mirjam I. Geerlings,et al.  APOE ε4 differentially influences change in memory performance depending on age. The SMART-MR study , 2012, Neurobiology of Aging.

[5]  S. Salloway,et al.  Cerebral Cortical Arteriolar Angiopathy, Vascular Beta-Amyloid, Smooth Muscle Actin, Braak Stage, and APOE Genotype , 2008, Stroke.

[6]  Wiro J. Niessen,et al.  Vascular risk factors, apolipoprotein E, and hippocampal decline on magnetic resonance imaging over a 10-year follow-up , 2012, Alzheimer's & Dementia.

[7]  W. Poon,et al.  Apolipoprotein E pathology in vascular dementia. , 2014, International journal of clinical and experimental pathology.

[8]  P. Wolf,et al.  Interactive effects of apolipoprotein E type 4 genotype and cerebrovascular risk on neuropsychological performance and structural brain changes. , 2010, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[9]  C. Haass,et al.  Amyloid-β protein modulates the perivascular clearance of neuronal apolipoprotein E in mouse models of Alzheimer’s disease , 2011, Journal of Neural Transmission.

[10]  B. Hyman,et al.  Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy , 1995 .

[11]  Paul M. Matthews,et al.  Reduced cerebrovascular reactivity in young adults carrying the APOE ε4 allele , 2015, Alzheimer's & Dementia.

[12]  P. Wesseling,et al.  Amyloid‐β‐induced Degeneration of Human Brain Pericytes Is Dependent on the Apolipoprotein E Genotype , 2000, Annals of the New York Academy of Sciences.

[13]  S. Rapcsak,et al.  Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers , 2011, Neurology.

[14]  A. Brickman,et al.  APOE ε4 and risk for Alzheimer's disease: Do regionally distributed white matter hyperintensities play a role? , 2014, Alzheimer's & Dementia.

[15]  F. Crawford,et al.  A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier , 2012, Neurodegenerative Diseases.

[16]  W. Jagust,et al.  The Role of APOE ∊4 in Modulating Effects of Other Risk Factors for Cognitive Decline in Elderly Persons , 1999 .

[17]  Farzaneh A. Sorond,et al.  Apolipoprotein E, Carbon Dioxide Vasoreactivity, and Cognition in Older Adults: Effect of Hypertension , 2015, Journal of the American Geriatrics Society.

[18]  K. Blennow,et al.  A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality , 1998, Journal of neurology, neurosurgery, and psychiatry.

[19]  R. Doody,et al.  Does APO ε4 correlate with MRI changes in Alzheimer's disease? , 2000 .

[20]  G. Waldemar,et al.  The apolipoprotein E epsilon4-allele and antihypertensive treatment are associated with increased risk of cerebral MRI white matter hyperintensities. , 2007, Acta neurologica Scandinavica.

[21]  T. Beach,et al.  Cortical and Leptomeningeal Cerebrovascular Amyloid and White Matter Pathology in Alzheimer’s Disease , 2003, Molecular medicine.

[22]  David D Shin,et al.  Effect of Mild Cognitive Impairment and APOE Genotype on Resting Cerebral Blood Flow and its Association with Cognition , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  M. Toborek,et al.  PPAR Agonist-Mediated Protection against HIV Tat-Induced Cerebrovascular Toxicity is Enhanced in MMP-9-Deficient Mice , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[24]  F. Calon,et al.  Human Apolipoprotein E ε4 Expression Impairs Cerebral Vascularization and Blood—Brain Barrier Function in Mice , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  R. Carare,et al.  Disruption of Arterial Perivascular Drainage of Amyloid-β from the Brains of Mice Expressing the Human APOE ε4 Allele , 2012, PloS one.

[26]  Clare E. Mackay,et al.  The effects of APOE-ε4 on the BOLD response , 2012, Neurobiology of Aging.

[27]  Sterling C. Johnson,et al.  Neuroimage: Clinical White Matter Microstructure in Late Middle-age: Effects of Apolipoprotein E4 and Parental Family History of Alzheimer's Disease , 2022 .

[28]  S. Resnick,et al.  APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. , 2010, Archives of neurology.

[29]  Joanna M. Wardlaw,et al.  Alzheimer's disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936 , 2014, Neurobiology of Aging.

[30]  M. Vitek,et al.  The apoE-mimetic Peptide, COG1410, Improves Functional Recovery in a Murine Model of Intracerebral Hemorrhage , 2012, Neurocritical Care.

[31]  D. Graham,et al.  The Apolipoprotein E ∈2 Allele and the Pathological Features in Cerebral Amyloid Angiopathy-related Hemorrhage , 1999 .

[32]  P. Scheltens,et al.  Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. , 1999, Archives of neurology.

[33]  M. Yamada,et al.  Cerebral amyloid angiopathy in the elderly: the clinicopathological features, pathogenesis, and risk factors. , 1997, Journal of medical and dental sciences.

[34]  J. Nicoll,et al.  High frequency of apolipoprotein E ϵ2 allele is specific for patients with cerebral amyloid angiopathy-related haemorrhage , 1998, Neuroscience Letters.

[35]  P. Scheltens,et al.  Apolipoprotein E ϵ4 Allele, Temporal Lobe Atrophy, and White Matter Lesions in Late-Life Dementias , 1999 .

[36]  T. Berzin,et al.  Microvascular injury and blood–brain barrier leakage in Alzheimer's disease , 2007, Neurobiology of Aging.

[37]  J. Attems,et al.  Capillary cerebral amyloid angiopathy identifies a distinct APOE ε4-associated subtype of sporadic Alzheimer’s disease , 2010, Acta Neuropathologica.

[38]  J. Jia,et al.  Meta-analysis of APOE4 allele and outcome after traumatic brain injury. , 2008, Journal of neurotrauma.

[39]  Berislav V. Zlokovic,et al.  Apolipoprotein E controls cerebrovascular integrity via cyclophilin A , 2012, Nature.

[40]  Anders M. Dale,et al.  Cerebral perfusion and oxygenation differences in Alzheimer's disease risk , 2009, Neurobiology of Aging.

[41]  Lars Nyberg,et al.  The APOE ε4 allele in relation to brain white-matter microstructure in adulthood and aging. , 2014, Scandinavian journal of psychology.

[42]  Jan Cees de Groot,et al.  Interaction Between Hypertension, apoE, and Cerebral White Matter Lesions , 2004, Stroke.

[43]  L. Baxter,et al.  APOE &egr;4 Is Associated With Exacerbation of Cognitive Decline in Patients With Multiple Sclerosis , 2011, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[44]  M. Brug,et al.  Lack of Widespread BBB Disruption in Alzheimer’s Disease Models: Focus on Therapeutic Antibodies , 2015, Neuron.

[45]  J. Zhou,et al.  Decreased cerebral blood flow velocity in apolipoprotein E epsilon4 allele carriers with mild cognitive impairment. , 2007, European journal of neurology.

[46]  J. Ringman,et al.  Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease. , 2014, JAMA neurology.

[47]  Alexandra Bell,et al.  Turning point: Mark Lawrence , 2012, Nature.

[48]  J. Nicoll,et al.  High frequency of apolipoprotein E epsilon 2 allele is specific for patients with cerebral amyloid angiopathy-related haemorrhage. , 1998, Neuroscience letters.

[49]  S. Estus,et al.  Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk , 2014, Molecular Neurodegeneration.

[50]  L. Thal,et al.  Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4. , 2000, Archives of neurology.

[51]  D. Na,et al.  Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) ε4 allele in the elderly: retrospective analysis of data from the CREDOS study. , 2012, The Journal of clinical psychiatry.

[52]  S. Rapcsak,et al.  Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes , 2011, Neurology.

[53]  L. Fratiglioni,et al.  Do cardiovascular risk factors explain the link between white matter hyperintensities and brain volumes in old age? A population‐based study , 2014, European journal of neurology.

[54]  Y. Stern,et al.  APOE genotype and cerebral blood flow in healthy young individuals. , 2003, JAMA.

[55]  B. Hyman,et al.  Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. , 1995, Annals of neurology.

[56]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[57]  Valerio Zerbi,et al.  Resting-State Functional Connectivity Changes in Aging apoE4 and apoE-KO Mice , 2014, The Journal of Neuroscience.

[58]  Thomas T. Liu,et al.  Increased hippocampal blood flow in sedentary older adults at genetic risk for Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[59]  L. Fratiglioni,et al.  Effects of vascular risk factors and APOE ε4 on white matter integrity and cognitive decline , 2015, Neurology.

[60]  J. Nicoll,et al.  Apolipoprotein E Genotype and Cerebral Amyloid Angiopathy‐related Hemorrhage , 2000, Annals of the New York Academy of Sciences.

[61]  G. Waldemar,et al.  The apolipoprotein E ɛ4‐allele and antihypertensive treatment are associated with increased risk of cerebral MRI white matter hyperintensities , 2007 .

[62]  H. Braak,et al.  Two Types of Sporadic Cerebral Amyloid Angiopathy , 2002, Journal of neuropathology and experimental neurology.

[63]  N. Pomara,et al.  Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. , 2013, JAMA neurology.

[64]  Manfred Kaps,et al.  Effect of ApoE ε4 Allele on Visual Evoked Potentials and Resultant Flow Coupling in Patients With Alzheimer , 2010, Journal of geriatric psychiatry and neurology.

[65]  H. Soininen,et al.  SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[66]  C. Sudlow,et al.  Genetic Determinants of White Matter Hyperintensities on Brain Scans: A Systematic Assessment of 19 Candidate Gene Polymorphisms in 46 Studies in 19 000 Subjects , 2009, Stroke.

[67]  K. Jellinger,et al.  Alzheimer’s disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy , 2005, Acta Neuropathologica.

[68]  R. Marioni,et al.  Differential effects of the APOE e4 allele on different domains of cognitive ability across the life-course , 2015, European Journal of Human Genetics.

[69]  S. Love,et al.  APOE and cerebral amyloid angiopathy in the elderly , 2003, Neuroreport.

[70]  David W Fardo,et al.  APOE-ε2 and APOE-ε4 correlate with increased amyloid accumulation in cerebral vasculature. , 2013, Journal of neuropathology and experimental neurology.

[71]  J. Provias,et al.  Correlation analysis of capillary APOE, VEGF and eNOS expression in Alzheimer brains. , 2011, Current Alzheimer research.

[72]  J. Felblinger,et al.  Association Study of Gene Polymorphisms Involved in Vascular Alterations in Elderly Hypertensives with Subjective Memory Complaints , 2010, Dementia and Geriatric Cognitive Disorders.

[73]  Pinal N. Kanabar,et al.  APOE‐modulated Aβ‐induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective , 2015, Journal of neurochemistry.

[74]  Maja A. A. Binnewijzend,et al.  Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease , 2013, Neurobiology of Aging.

[75]  W. Funkhouser,et al.  APOE Stabilization by Exercise Prevents Aging Neurovascular Dysfunction and Complement Induction , 2015, PLoS biology.

[76]  G. Jahng,et al.  Regional cerebral perfusion in patients with Alzheimer’s disease and mild cognitive impairment: effect of APOE Epsilon4 allele , 2012, Neuroradiology.

[77]  B T Hyman,et al.  Progression of Cerebral Amyloid Angiopathy: Accumulation of Amyloid-ß40 in Affected Vessels , 1998, Journal of neuropathology and experimental neurology.

[78]  S. Salloway,et al.  Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease , 2002, Journal of the Neurological Sciences.

[79]  L. Guoqing Immunotherapy for Alzheimers disease , 2006 .

[80]  P. Blackshear,et al.  APOε4 is associated with enhanced in vivo innate immune responses in human subjects. , 2014, The Journal of allergy and clinical immunology.

[81]  A. Członkowska,et al.  The APOE polymorphism and 1‐year outcome in ischemic stroke: genotype–gender interaction , 2007, Acta neurologica Scandinavica.

[82]  A. Smith,et al.  Cerebral Amyloid Angiopathy, Subcortical White Matter Disease and Dementia: Literature Review and Study in OPTIMA , 2015, Brain pathology.

[83]  L. Westlye,et al.  Effects of APOE on brain white matter microstructure in healthy adults , 2012, Neurology.

[84]  K. Lunetta,et al.  APOE genotype and MRI markers of cerebrovascular disease , 2013, Neurology.

[85]  A. Bokde,et al.  The ε4 genotype of apolipoprotein E and white matter integrity in Alzheimer's disease , 2014, Alzheimer's & Dementia.

[86]  Naftali Raz,et al.  Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. , 2012, Biochimica et biophysica acta.

[87]  Paul M. Matthews,et al.  Differential effects of the APOE genotype on brain function across the lifespan , 2011, NeuroImage.

[88]  R. Caselli,et al.  APOE ε4 Genotype and the Risk for Subjective Cognitive Impairment in Elderly Persons. , 2015, The Journal of neuropsychiatry and clinical neurosciences.

[89]  J. Rutledge,et al.  C-terminal interactions of apolipoprotein E4 respond to the postprandial state Published, JLR Papers in Press, April 21, 2006. , 2006, Journal of Lipid Research.

[90]  G. Salvato,et al.  Does apolipoprotein E genotype influence cognition in middle-aged individuals? , 2015, Current opinion in neurology.

[91]  Takashi Asada,et al.  Effect of plasma lipids, hypertension and APOE genotype on cognitive decline , 2012, Neurobiology of Aging.

[92]  Y. Hong,et al.  Interaction of white matter hyperintensities (WMHs) and apolipoprotein E (APOE) genotypes on cognition in patients with amnestic mild cognitive impairment (aMCI). , 2013, Archives of gerontology and geriatrics.

[93]  N. Shu,et al.  Effects of APOE promoter polymorphism on the topological organization of brain structural connectome in nondemented elderly , 2015, Human brain mapping.

[94]  P. Wolf,et al.  APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[95]  E. Weeber,et al.  APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease* , 2012, The Journal of Biological Chemistry.

[96]  A. Meyer-Lindenberg,et al.  Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer’s disease: a voxel-based lesion mapping study , 2015, Alzheimer's Research & Therapy.

[97]  B. Winblad,et al.  Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population. , 2006, Neurological research.

[98]  J. Geiger,et al.  Role of endolysosomes and cholesterol in the pathogenesis of Alzheimer's disease: Insights into why statins might not provide clinical benefit. , 2014, Austin journal of pharmacology and therapeutics.

[99]  M. Macavoy,et al.  Absence of an apolipoprotein E epsilon4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease. , 1998, Archives of neurology.

[100]  S. Kanba,et al.  Insulin resistance is associated with the pathology of Alzheimer disease , 2010, Neurology.

[101]  Khaled Restom,et al.  Assessment of Alzheimer's disease risk with functional magnetic resonance imaging: an arterial spin labeling study. , 2012, Journal of Alzheimer's disease : JAD.

[102]  J. Rutledge,et al.  The vascular contribution to Alzheimer's disease. , 2010, Clinical science.

[103]  D. Thal,et al.  Cerebral Small Vessel Disease-Induced Apolipoprotein E Leakage Is Associated With Alzheimer Disease and the Accumulation of Amyloid &bgr;-Protein in Perivascular Astrocytes , 2008, Journal of neuropathology and experimental neurology.

[104]  R. Vanderploeg,et al.  APOE genotype influences acquisition and recall following traumatic brain injury , 2002, Neurology.

[105]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[106]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[107]  C. Zarow,et al.  Cerebral amyloid angiopathy in Alzheimer disease is associated with apolipoprotein E4 and cortical neuron loss. , 1999, Alzheimer disease and associated disorders.

[108]  L M Bouter,et al.  Memory complaints and APOE-ε4 accelerate cognitive decline in cognitively normal elderly , 2001, Neurology.

[109]  S. Leurgans,et al.  APOE and cerebral amyloid angiopathy in community-dwelling older persons , 2015, Neurobiology of Aging.

[110]  I. Deary,et al.  APOE/TOMM 40 genetic loci, white matter hyperintensities, and cerebral microbleeds , 2015, International journal of stroke : official journal of the International Stroke Society.

[111]  S. Greenberg,et al.  Association of apolipoprotein E ϵ2 and vasculopathy in cerebral amyloid angiopathy , 1998, Neurology.

[112]  E. Mori,et al.  Effect of the Apolipoprotein E ε4 Allele on White Matter Hyperintensities in Dementia , 2000 .

[113]  Aad van der Lugt,et al.  Prevalence and Risk Factors of Cerebral Microbleeds: An Update of the Rotterdam Scan Study , 2010, Stroke.

[114]  T. Morgan,et al.  The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice , 2016, Neurobiology of Aging.

[115]  D. Graham,et al.  CLINICAL NEUROSCIENCE: Amyloid beta-protein length and cerebral amyloid angiopathy-related haemorrhage , 2000 .

[116]  P. Rossini,et al.  Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in Alzheimer's disease and vascular dementia. , 2013, Rejuvenation research.

[117]  L. Kuller,et al.  Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. , 2008, Archives of neurology.

[118]  Andrew R. Bender,et al.  Age-related differences in memory and executive functions in healthy APOE ɛ4 carriers: The contribution of individual differences in prefrontal volumes and systolic blood pressure , 2012, Neuropsychologia.

[119]  R N Kalaria,et al.  Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. , 1996, The American journal of pathology.

[120]  David M Holtzman,et al.  Human Apoe Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance Nih Public Access , 2022 .

[121]  H. Soininen,et al.  Longitudinal SPECT study in Alzheimer’s disease: relation to apolipoprotein E polymorphism , 1998, Journal of neurology, neurosurgery, and psychiatry.

[122]  B. Zlokovic,et al.  Accelerated pericyte degeneration and blood–brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[123]  F. Crawford,et al.  Stimulation of the Retinoid X Receptor Facilitates Beta-Amyloid Clearance Across the Blood–Brain Barrier , 2012, Journal of Molecular Neuroscience.

[124]  A. Paetau,et al.  Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+). , 2015, Journal of Alzheimer's disease : JAD.

[125]  F. Calon,et al.  Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2 , 2014, Journal of neurochemistry.

[126]  S. Love,et al.  APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. , 2003, Neuropathology and applied neurobiology.

[127]  D. Holtzman,et al.  Human Apolipoprotein E4 Alters the Amyloid-β 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model , 2005, The Journal of Neuroscience.

[128]  A. Karch,et al.  Investigating the Association of ApoE Genotypes with Blood-Brain Barrier Dysfunction Measured by Cerebrospinal Fluid-Serum Albumin Ratio in a Cohort of Patients with Different Types of Dementia , 2013, PloS one.

[129]  Huaxi Xu,et al.  Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice , 2015, Molecular Neurodegeneration.

[130]  A. Hafezi-Moghadam,et al.  ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. , 2007, American journal of physiology. Cell physiology.

[131]  D. Mann,et al.  Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[132]  J. M. Rusted,et al.  APOE e4 polymorphism in young adults is associated with improved attention and indexed by distinct neural signatures , 2013, NeuroImage.

[133]  D. Graham,et al.  The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. , 1999, Journal of neuropathology and experimental neurology.

[134]  Yunfei Wei,et al.  ApoE-Deficient Promotes Blood–Brain Barrier Disruption in Experimental Autoimmune Encephalomyelitis via Alteration of MMP-9 , 2014, Journal of Molecular Neuroscience.

[135]  B. Winblad,et al.  Cerebrovascular disease, APOE ϵ4 allele and cognitive decline in a cognitively normal population , 2006 .

[136]  A. Paetau,et al.  Cerebral amyloid angiopathy in a 95+ cohort: complement activation and apolipoprotein E (ApoE) genotype , 2005, Neuropathology and applied neurobiology.

[137]  C. Mun,et al.  Impact of Apolipoprotein E4 Polymorphism on the Gray Matter Volume and the White Matter Integrity in Subjective Memory Impairment without White Matter Hyperintensities: Voxel‐Based Morphometry and Tract‐Based Spatial Statistics Study under 3‐Tesla MRI , 2016, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[138]  E. Mori,et al.  Effect of the apolipoprotein E epsilon4 allele on white matter hyperintensities in dementia. , 2000, Stroke.

[139]  Takashi Asada,et al.  Apolipoprotein E Genotype and Early Alzheimer's Disease: A Longitudinal SPECT Study , 2003, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[140]  B. Hyman,et al.  APOEε2 Is Associated With Milder Clinical and Pathological Alzheimer’s Disease (S16.005) , 2015 .

[141]  L. Launer,et al.  Cerebral amyloid angiopathy and cognitive function: The HAAS autopsy study , 2002, Neurology.

[142]  R. Mahley,et al.  Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. , 1982, The Journal of biological chemistry.

[143]  C. DeCarli,et al.  Impact of apolipoprotein E epsilon4 and vascular disease on brain morphology in men from the NHLBI twin study. , 1999, Stroke.

[144]  C. Holmes,et al.  Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy , 2014, Acta Neuropathologica.

[145]  F. Fazekas,et al.  Apolipoprotein E4allele in the normal elderly: neuropsychologic and brain MRI correlates , 1996, Clinical genetics.

[146]  M. Verbeek,et al.  Apolipoprotein E Genotype Regulates Amyloid-β Cytotoxicity , 2005, The Journal of Neuroscience.

[147]  C. DeCarli,et al.  Impact of Apolipoprotein E ε4 and Vascular Disease on Brain Morphology in Men From the NHLBI Twin Study , 1999 .

[148]  M. Frosch,et al.  Cerebral amyloid angiopathy with and without hemorrhage , 2015, Neurology.

[149]  N. Inestrosa,et al.  Peroxisome Proliferator-activated Receptors and Alzheimer's Disease: Hitting the Blood–Brain Barrier , 2013, Molecular Neurobiology.

[150]  S. Strickland,et al.  The APOE ε4/ε4 Genotype Potentiates Vascular Fibrin(Ogen) Deposition in Amyloid-Laden Vessels in the Brains of Alzheimer's Disease Patients , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[151]  B. Hyman,et al.  Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. , 1998, Neurology.

[152]  W. Jagust,et al.  The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. , 1999, JAMA.

[153]  Yuehua Wu,et al.  Apolipoprotein E-Mimetic COG1410 Reduces Acute Vasogenic Edema following Traumatic Brain Injury. , 2016, Journal of neurotrauma.

[154]  David D Shin,et al.  Interaction of age and APOE genotype on cerebral blood flow at rest. , 2013, Journal of Alzheimer's disease : JAD.

[155]  G. Bu,et al.  Apolipoprotein E Inhibits Cerebrovascular Pericyte Mobility through a RhoA Protein-mediated Pathway* , 2015, The Journal of Biological Chemistry.

[156]  S. Love,et al.  APOEɛ4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of Aβ protein , 2003 .

[157]  Thomas Wisniewski,et al.  Immunotherapy for Alzheimer's disease. , 2014, Biochemical pharmacology.

[158]  Richard J. Caselli,et al.  Amyloid load in nondemented brains correlates with APOE e4 , 2010, Neuroscience Letters.

[159]  D. Mann,et al.  Patterns of cerebral amyloid angiopathy define histopathological phenotypes in Alzheimer's disease , 2014, Neuropathology and applied neurobiology.

[160]  R. Doody,et al.  Does APO epsilon4 correlate with MRI changes in Alzheimer's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.

[161]  G. Bu,et al.  Apolipoprotein E Regulates the Integrity of Tight Junctions in an Isoform-dependent Manner in an in Vitro Blood-Brain Barrier Model* , 2011, The Journal of Biological Chemistry.

[162]  C. Sudlow,et al.  APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[163]  D. Graham,et al.  High frequency of apolipoprotein E ϵ2 Allele in hemorrhage due to cerebral amyloid angiopathy , 1997, Annals of neurology.

[164]  O. Paulson,et al.  Single Photon Emission Computed Tomography and Apolipoprotein E in Alzheimer's Disease: Impact of the ε4 Allele on Regional Cerebral Blood Flow , 2001 .